Breast Recurrence Score Test Market - Growth Drivers and Challenges
Growth Drivers
- Increasing Incidence of Breast Cancer: Breast cancer is one of the most common cancer types worldwide, and its incidence has been steadily rising. According to the World Cancer Research Fund, breast cancer accounted for nearly 12% of new cancer cases in 2020, making it the most common cancer among women globally. As the incidence of breast cancer continues to grow, the demand for accurate diagnostic tools such as the Breast Recurrence Score Test increases. The test helps in stratifying patients into different risk categories, enabling personalized treatment decisions, which can lead to more efficient healthcare resource utilization and better outcomes for patients.
- Expanding Awareness and Education: The breast cancer community has been actively promoting awareness and education. Organizations like Susan G. Komen have played a crucial role in educating both patients and healthcare providers about the importance of early detection and the significance of diagnostic tests like the Breast Recurrence Score Test. Increased awareness has led to more patients and healthcare professionals seeking out and prescribing these tests.
- Patient-Centered Care: Modern healthcare is increasingly focused on patient-centered care. Patients are becoming more engaged in their treatment decisions and are seeking options that offer the best outcomes with minimal side effects. The Breast Recurrence Score Test aligns perfectly with this trend by providing patients with information that empowers them to make informed choices about their treatment.
Challenges
- Cost and Accessibility: One of the primary challenges is the cost of the test and its accessibility. While insurance coverage has expanded in recent years, not all patients have access to the test, and the out-of-pocket costs can be prohibitive for some. This can lead to disparities in care, where some patients may not benefit from the test due to financial constraints. While insurance coverage for the test has improved over the years, there can still be significant variability in the extent of coverage. Some insurance policies may cover the entire cost of the test, while others may cover only a portion of it. This variability can lead to inconsistencies in patient access to the test, depending on their insurance provider and policy type.
- Variability in Insurance Coverage
- Awareness and Knowledge among Healthcare Personnel
Breast Recurrence Score Test Market Size and Forecast:
|
Base Year |
2025 |
|
Forecast Year |
2026-2035 |
|
CAGR |
6.3% |
|
Base Year Market Size (2025) |
USD 4.16 billion |
|
Forecast Year Market Size (2035) |
USD 7.66 billion |
|
Regional Scope |
|
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of breast recurrence score test is estimated at USD 4.4 billion.
The global breast recurrence score test market size was more than USD 4.16 billion in 2025 and is anticipated to grow at a CAGR of over 6.3%, reaching USD 7.66 billion revenue by 2035.
The Asia Pacific region in the breast recurrence score test market is set to command a leading 38% share by 2035, underpinned by the shift toward patient-centered care.
Key players in the market include Genomic Health, Inc., Agendia, Inc., NanoString Technologies, Inc., Myriad Genetics, Inc., Thermo Fisher Scientific, Inc., Illumina, Inc.
